Sort
8,912 grants matching “sars cov 2”
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
$9,754,127Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
RADX TECH - TALIS BIOMEDICAL HIGHLY SCALABLE SARS-COV-2 RNA DETECTION IN MINUTES
$9,750,000Jennifer Baldwin · · N02 · FY2021 · HL
Inter- and Intra-Species Comparative Sequencing
$9,722,540James Thomas · National Human Genome Research Institute · ZIB · FY2023 · HG
Inter- and Intra-Species Comparative Sequencing
$9,523,646James Thomas · National Human Genome Research Institute · ZIB · FY2024 · HG
Tulane National Primate Research Center
$9,304,973Lee Hamm · Tulane University Of Louisiana · P51 · FY2024 · OD
Tulane National Primate Research Center
$9,304,973Lee Hamm · Tulane University Of Louisiana · P51 · FY2023 · OD
Tulane National Primate Research Center
$9,304,973Lee Hamm · Tulane University Of Louisiana · P51 · FY2025 · OD
GENETIC EPIDEMIOLOGY OF COPD (COPD GENE) 2024 - 2025 TASK ORDER FOR TASK AREA A: COLLECTION OF COPDGENE STUDY DATA AND BIOSPECIMENS AND OVERSIGHT OF THE COPDGENE STUDY.
$9,298,220James Cappo · National Jewish Health · N01 · FY2024 · HL
COPD GENE - GENETIC EPIDEMIOLOGY OF COPD - TASK AREA A: YEAR 3 - AUGUST 10, 2025 - AUGUST 9, 2026
$9,292,344Lee S Newman · National Jewish Health · N01 · FY2025 · HL
Oral small molecule inhibitors of NSP4-mediated membrane-associated RNA replication of SARS-CoV-2 and other RNA viruses
$9,266,568Jeffrey S Glenn · Stanford University · U19 · FY2022 · AI
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
$9,214,781Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2020 · AI
Structure-based design of broadly protective coronavirus vaccines
$9,065,441Neil King · University Of Washington · P01 · FY2022 · AI
CoVPN 3501: Eli Lilly (LY3819253) Protocol Funding
$8,980,894Myron S Cohen · Family Health International · UM1 · FY2021 · AI
Programmable antivirals: Targeting viral RNA secondary structures with LNAs and small molecules
$8,915,196Jeffrey S Glenn · Stanford University · U19 · FY2022 · AI
International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
$8,758,469Sally Hunsberger · Leidos Biomedical Research, Inc. · N01 · FY2021 · AI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations
$8,725,158Gabriel Alejandro De Erausquin · University Of Texas Hlth Science Center · U19 · FY2023 · AG
CoVPN 5001 A Prospective Study of Acute Immune Responses to SARS-CoV-2 Infection LC 3
$8,696,751Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
Interactions of SARS-CoV-2 infection and genetic variation on the risk of cognitive decline and Alzheimerâs disease in Ancestral and Admixed Populations
$8,610,822Gabriel Alejandro De Erausquin · University Of Texas Hlth Science Center · U19 · FY2024 · AG
The NYU Childrenâs Health & Environment Study: an ECHO Cohort
$8,599,294Leonardo Trasande · New York University School Of Medicine · UG3 · FY2023 · OD
RADX PROGRAM: TECH PROJECT NO 6114 FLUIDIGM ADVANTA DX SARS-COV-2 RT-PCR ASSAY FOR SALIVA
$8,580,056Andrew Quong · Fluidigm Corporation · N02 · FY2021 · HL
The Baltimore Longitudinal Study of Aging
$8,568,920Eleanor M Simonsick · National Institute On Aging · ZIA · FY2024 · AG
HTS Core
$8,530,970Kristen A Johnson · Scripps Research Institute, The · U19 · FY2022 · AI
Fragment-to-lead and target validation
$8,477,219John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2022 · AI
Core E: Cellular and Organismic Systems for Antiviral Testing
$8,451,808Ryan Langlois · University Of Minnesota · U19 · FY2022 · AI
Steroid Treatment for Severe Acute Respiratory Infection (STAR) trial
$8,346,180Leidos Biomedical Research, Inc. · N01 · FY2025 · AI